Videos

Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...

Jennifer Brown, MD, PhD, found that zanubrutinib may provide further efficacy, safety, and improved progression-free survival compared to ibrutinib among patients with relapsed/refractory CLL and SLL.

At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...

Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.

Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...

Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.

Dr Joshua Richter, associate professor of medicine at Tisch Cancer Institute, discusses his presentation on the effects of immune therapies on infection in patients with multiple myeloma.

Michael Kolodziej, MD, Advisor, Canopy, discusses at the 2022 Oncology Clinical Pathways Congress how electronic patient-reported outcomes and electronic engagement with patients can aid improve outcomes.